Endologix Inc.

292 articles with Endologix Inc.

• Endologix Reports First Quarter 2019 Financial Results

  5/2/2019

  Today announced financial results for the first quarter ended March 31, 2019.

• Endologix, Inc. to Announce First Quarter 2019 Financial Results on May 2, 2019

  4/15/2019

  Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2019 after the market close on Thursday, May 2, 2019.

• Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants

  4/1/2019

  The Company reports preliminary revenue for the first quarter ending March 31, 2019 of at least $35 million

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 20, 2019

  3/20/2019

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced the grant of inducement equity awards to nine newly hired employees.

• Endologix Announces Approval of Reverse Stock Split

  3/5/2019

  Endologix, Inc. previously announced that a proposal was approved at its Special Meeting of Stockholders, held February 22, 2019, authorizing its Board of Directors to amend the Company's certificate of incorporation.

• Endologix Reports Fourth Quarter and Fiscal Year 2018 Financial Results

  2/25/2019

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced financial results for the fourth quarter and fiscal year ended December 31, 2018.

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  2/11/2019

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced the grant of inducement equity awards to eight newly hired employees.

• Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on February 25, 2019

  1/29/2019

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced that it will report financial results for the fourth quarter and fiscal year 2018 after the market close on Monday, February 25, 2019.

• Endologix Provides Update on Previously Announced Voluntary Nellix System Recall

  1/22/2019

  Endologix Inc.®  (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the EC Certificate of Conformity (CE Mark) for the Nellix EndoVascular Aneurysm Sealing System (Nellix System) has been suspended by its Notified Body, GMED, following a voluntary recall and Field Safety Notification (FSN) issued by Endologix on January 4, 2019.

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on December 10, 2018

  1/11/2019

  Endologix, Inc. announced today the grant of inducement equity awards to a newly hired executive (the “Awardee”).

• Endologix Appoints John D. Zehren as Chief Commercial Officer

  1/10/2019

  Endologix, Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John D. Zehren as the Company’s Chief Commercial Officer, effective as of January 7, 2019 (the “Effective Date”).

• Endologix Announces Fourth Quarter and Full-Year 2018 Preliminary Financial Results and Provides 2019 Financial Guidance

  1/7/2019

  Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2018 is expected to be approximately $34 million.

• Endologix Takes Decisive Action to Optimize Patient Outcomes by Ensuring Nellix System Used Only within Current Indications

  1/4/2019

  Endologix® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, announced today that in order to ensure optimal outcomes for patients, unrestricted sales and use of the Nellix System will cease immediately, and the product will only be available for use under clinical protocol with pre-screened patients that adhere to the current indications.

• Endologix, Inc. to Present at the J.P. Morgan Healthcare Conference

  12/20/2018

  Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference at 4:30 p.m. PT on Monday, January 7, 2019 in San Francisco, CA.

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on December 5, 2018

  12/13/2018

  Endologix, Inc. announced today the grant of inducement equity awards to three newly hired employees (together, the “Awardees”).

• Endologix Honors Innovators of Aortic Therapy at VEITHsymposium

  11/15/2018

  Endologix, Inc. today honored four innovators of aortic therapy at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium®), a meeting of endovascular specialists highlighting developments in the treatment of vascular disease.

• Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on November 6, 2018

  11/8/2018

  Endologix, Inc. announced today the grant of inducement equity awards to three newly hired employees (together, the “Awardees”).

• Endologix Reports Third Quarter 2018 Financial Results

  11/1/2018

  Endologix, Inc. today announced financial results for the third quarter ended September 30, 2018.

• Endologix, Inc. to Present at Two Investor Conferences in November

  10/29/2018

  Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will present at the following two investor conferences in November:

• Endologix Announces Pricing of Public Offering of Common Stock for Net Proceeds of $20.0 million

  10/25/2018

  Endologix, Inc. announced today the pricing of a registered underwritten public offering of its common stock for net proceeds of $20.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Endologix.